Welcome to our dedicated page for HAWKINS SEC filings (Ticker: HWKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hawkins, Inc. filings document formal disclosures for a Minnesota operating company in water treatment and specialty ingredients. Its recent 8-K filings include quarterly results furnished under Item 2.02, Regulation FD materials presenting historical financial information aligned to reporting segments, and shareholder voting results from the annual meeting.
The filing record covers the company’s Water Treatment, Food & Health Sciences, and Industrial Solutions segment framework, along with governance matters such as director elections, auditor ratification, and advisory executive compensation votes. These documents also provide the official record for material-event reporting, financial communications, and changes in how Hawkins presents its operating segments.
Hawkins Inc director Jeffrey E. Spethmann received a grant of 721 shares of common stock on July 29, 2026, recorded at $0.00 per share. Following this award, he directly holds 6,639.103 shares, including 7.103 shares acquired June 15, 2026 under the dividend reinvestment plan.
Stauber Daniel J reported acquisition or exercise transactions in this Form 4 filing.
Hawkins Inc director Daniel J Stauber received a grant of 721 shares of common stock on July 29, 2026 at $0.00 per share. Following this award, he directly holds 35,497.8812 shares, including 38.8082 shares from a dividend reinvestment plan and 175 shares from an employee stock purchase plan.
Hawkins Inc director James T. Thompson reported a grant of 721 shares of Common Stock on 2026-07-29, classified as a grant, award, or other acquisition at a reported price of $0.0000 per share. After this award, his directly held Hawkins common shares stood at 38,916.
Hawkins, Inc. reported first-quarter fiscal 2027 sales of $315.7 million, up 8% from $293.3 million a year earlier, with all three segments growing more than 5%. Gross margin compressed to 23.4% from 24.7%, reflecting higher LIFO charges and freight costs. Operating income fell 6% to $38.7 million, and net income was $28.3 million versus $29.2 million, with diluted EPS of $1.35 compared with $1.40.
Water Treatment sales rose to $158.3 million, Food & Health Sciences to $97.3 million, and Industrial Solutions to $60.1 million. Operating cash flow increased to $35.2 million, funding $11.6 million of capex and the $3.6 million Aqua-Chem acquisition. Cash was $8.0 million and debt under the $400 million Revolving Loan Facility remained $244.0 million at a 4.3% effective rate. The company paid a $0.19 per-share dividend and repurchased 45,196 shares for about $7.0 million, with 686,348 shares still available under its buyback authorization.
Hawkins, Inc. reported first-quarter fiscal 2027 results with record revenue of $315.7 million, up 8% from a year earlier, as all three segments grew: Water Treatment sales rose 6% to $158.3 million, Food & Health Sciences 9% to $97.3 million, and Industrial Solutions 10% to $60.1 million. Gross profit reached a record $74.0 million, up 2%, though gross margin declined to 23% of sales from 25% due to a larger LIFO reserve headwind and unrecovered freight costs. Net income was $28.3 million and diluted EPS $1.35, both down modestly from $29.2 million and $1.40.
Adjusted EBITDA was a record $56.9 million, up 1%, with trailing twelve‑month adjusted EBITDA of $179.8 million. Hawkins generated operating cash flow of $35.2 million and free cash flow of $23.5 million, which it used to repurchase $7.0 million of stock, pay $4.0 million in dividends, and acquire Aqua‑Chem, Inc. for $3.6 million to support its Water Treatment growth strategy. Total debt stood at $244.0 million, with a leverage ratio of 1.36x trailing adjusted EBITDA, and management highlighted a strong balance sheet and an expectation of a 25%–27% full‑year effective tax rate.
Hawkins, Inc. is calling a fully virtual annual shareholder meeting on July 29, 2026. Shareholders of record as of June 5, 2026, holding 20,906,400 common shares, may vote online, by phone, mail, or during the live webcast.
Investors are asked to elect eight directors, ratify Deloitte & Touche LLP as auditor for the year ending March 28, 2027, and approve a non-binding “say‑on‑pay” vote on executive compensation. The board recommends voting FOR all three proposals.
The proxy details an independent board majority, active audit, compensation, and governance committees, and a performance‑based pay program. For fiscal 2026, CEO Patrick H. Hawkins received total compensation of $3.6 million, heavily weighted to performance‑linked stock and incentives tied to income before income taxes and segment profitability.
HAWKINS INC officer Dan Louismet, who serves as VP, General Counsel and Secretary, has filed a Form 3 showing his beneficial ownership in the company. The filing reports direct ownership of 6.0050 shares of Hawkins common stock, providing a baseline view of his insider equity position.
Hawkins, Inc. filed a report describing a leadership classification change. On May 13, 2026, Vice President – Stauber Shirley A. Rozeboom was determined to no longer be an executive officer of the company, effective the same day.
The change is described as part of a planned transition related to a realignment of reporting segments that first took effect for the fiscal year ended March 29, 2026. Ms. Rozeboom continues to be employed by Hawkins, Inc.
HAWKINS INC vice president of Health and Nutrition, Shirley A. Rozeboom, reported routine equity compensation activity. She received a grant of 1,906 shares of Common Stock on May 13, 2026, bringing her direct holdings to 34,087.8625 shares. Earlier, on March 30, 2026, 3,608 shares were withheld at $151.62 per share to satisfy tax obligations, a non‑market disposition. Her holdings also reflect additional shares acquired through the issuer’s dividend reinvestment and employee stock purchase plans.